Advertisement

CNS Drugs

, Volume 33, Issue 1, pp 9–16 | Cite as

Opioidergic Agents as Antidepressants: Rationale and Promise

  • Parnika P. SaxenaEmail author
  • J. Alexander Bodkin
Leading Article
  • 90 Downloads

Abstract

Research concerning psychiatric issues relating to opioid drugs currently focuses primarily on their role in reinforcing addictive behaviors, given the recent proliferation of lethal abuse of illicit opiates in the United States and around the world. In contrast, this article will review the mechanism of action of opioids in affective disorders and the available evidence and potential for their use, especially in the treatment of resistant major depression. Buprenorphine is the opioid derivative of special interest; we review this and other opioid derivatives, highlighting the growing role of opioids in treating depressive illnesses and other related psychopathologies.

Notes

Compliance with Ethical Standards

Conflict of Interest

Parnika Saxena has no conflicts of interest to declare. J. Alexander Bodkin has a potential conflict due to longstanding efforts to advance the development of buprenorphine as an effective treatment for resistant depressive illness. He has helped Alkermes to engage in a development program of a buprenorphine/samidorphan preparation for use as an adjunctive treatment for resistant depression. This guidance was provided gratis; however, compensation was provided for participation in annual day-long group meetings with a group of academics held by Alkermes in Boston. His lab was also provided with funding for their work on a study on the long-term safety and efficacy of Alkermes’s buprenorphine/samidorphan preparation. Dr Bodkin will not benefit financially if the Alkermes preparation is approved and marketed, nor will he be harmed financially if it is not approved. Dr Bodkin authored one of the first American studies of buprenorphine in depression in 1995 and is one of the leading experts in the US on the use of opioids in depressive illness. He has assessed legal cases over the years as an expert on behalf of psychiatrists facing regulatory or civil litigation for having used opioids in treating resistant depression.

Funding

No sources of funding were used to assist with the preparation of this review.

References

  1. 1.
    Goodman and Gilman’s. The pharmacological basis of therapeutics, 13th edn. Dec 5, 2017 by Laurence Brunton and Bjorn Knollmann; 2017.Google Scholar
  2. 2.
    Brownstein MJ. A brief history of opiates, opioid peptides and opioid receptors. Proc Natl Acad Sci USA. 1993;90:5391–3.Google Scholar
  3. 3.
    Baraka A. Historical aspects of opium. Middle East J Anesthesiol. 2000;15:423–36.Google Scholar
  4. 4.
    Weber MM, Emrich HM. Current and historical concepts of opiate treatment in psychiatric disorders. Int Clin Psychopharmacol. 1988;3(3):255–66.Google Scholar
  5. 5.
    Kraeplin E. Manic depressive illness and paranoia. Edinburgh: Livingstone; 1921.Google Scholar
  6. 6.
    Mayer-Gross W, Slater E, Roth M. Clinical psychiatry. Baltimore: Williams and Wilkins; 1954.Google Scholar
  7. 7.
    Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.Google Scholar
  8. 8.
    Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.Google Scholar
  9. 9.
    Tenor Peter L. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis. 2008;27(3):49–65.Google Scholar
  10. 10.
    Contet C, Kieffer BL, Befort K. Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol. 2004;14(3):370–8.Google Scholar
  11. 11.
    Lutz P, Kieffer B. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013;36(3):195–206.Google Scholar
  12. 12.
    Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69(suppl E1):4–7.Google Scholar
  13. 13.
    Svingos AL, Chavkin C, Colago EE, Pickel VM. Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse. 2001;42(3):185–92.Google Scholar
  14. 14.
    Carlezon W Jr, Beguin C, Knoll AT, Cohen BM. Kappa opioid ligands in the study and treatment of mood disorders. Pharmacol Ther. 2009;123:334–43.Google Scholar
  15. 15.
    Bear DM, Kessler RM. United States Patent 8,883,831; 2014a.Google Scholar
  16. 16.
    Bear DM, Kessler RM. US Patent Application PCT/US2014/013874. Washington, DC; 2014b.Google Scholar
  17. 17.
    Mischoulon D, Hylek L, Yeung AS, Clain AJ, Baer L, Cusin C, Ionefscu DF, Alpert JE, Soskin DP, Fava M. Randomized, proof of concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017;208:6–14.Google Scholar
  18. 18.
    Berrocos E, Sanchez-Blazquez P, Garzón J, Mico JA. Opiates as antidepressants. Curr Pharm Design. 2009;15:1612–22.Google Scholar
  19. 19.
    Lauterbach EC. Treatment resistant depression with loss of antidepressant response: rapid—acting antidepressant action of dextromethorphan, a possible treatment bridging molecule. Psychopharmacol Bull. 2016;46(2):53–8.Google Scholar
  20. 20.
    Snyder CB, Pert SH. Opiate receptor: demonstration in nervous tissue. Science. 1973;179(4077):1011–4.Google Scholar
  21. 21.
    Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav. 2003;43(1):60–6.Google Scholar
  22. 22.
    Vuong C, Van Uum SH, O’Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31(1):98–132.Google Scholar
  23. 23.
    Dickenson AH. NMDA receptor antagonists: interactions with opioids. Acta Anaesthesiol Scand. 1997;41(1 Pt 2):112–5.Google Scholar
  24. 24.
    Schwartz-Lifshitz M, Zalsman G, Giner L, Oquendo MA. Can we really prevent suicide? Curr Psychiatry Rep. 2012;14(6):624–33.Google Scholar
  25. 25.
    Gross-Isseroff R, Dillon KA, Israeli M, Biegon A. Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Res. 1990;530(2):312–6.Google Scholar
  26. 26.
    Gabilondo AM, Meana JJ, García-Sevilla JA. Increased density of mu-opioid receptors in the postmortem brain of suicide victims. Brain Res. 1995;682(1–2):245–50.Google Scholar
  27. 27.
    Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63(11):1199–208.Google Scholar
  28. 28.
    Scarr E, Money TT, Pavey G, Neo J, Dean B. Mu opioid receptor availability in people with psychiatric disorders who died by suicide: a case control study. BMC Psychiatry. 2012;28(12):126.Google Scholar
  29. 29.
    Kosten T, Morgan C, Kosten TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 1990;7:51–4.Google Scholar
  30. 30.
    Dean AJ, Bell J, Mascord DJ, Parker G, Christie MJ. A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. J Affect Disord. 2002;72:85–90.Google Scholar
  31. 31.
    Dean AJ, Bell J, Christie MJ, Mattick RP. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry. 2004;19:510–3.Google Scholar
  32. 32.
    Fava M, Memisoglu A, Thase ME, Bodkin JA, Trivedi MH, de Somer M, Du Y, Leigh-Pemberton R, DiPetrillo L, Silverman B, et al. Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry. 2016;173(5):499–508.Google Scholar
  33. 33.
    Leander JD. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology. 1987;26(9):1445–7.Google Scholar
  34. 34.
    Knoll AT, Carlezon WA. Dynorphin, stress, and depression. Brain Res. 2010;1314:56–73.Google Scholar
  35. 35.
    Thase ME, Stanford AD, Memisoglu A, Martin W, Claxton A, Bodkin JA, Trivedi MH, Fava M, Pathak S. Long-term efficacy, safety and tolerability of adjunctive ALKS 5461 as adjunctive treatment in patients with major depressive disorder enrolled in an ongoing Phase 3 study: poster session presented at American Psychiatric Association annual meeting. NY: NYC; 2018.Google Scholar
  36. 36.
    Emrich HM, Vogt P, Herz A, Kissling W. Antidepressant effects of buprenorphine. Lancet. 1982;2(8300):709.Google Scholar
  37. 37.
    Morgan L, Calloway E. Buprenorphine responders. Biol Psychiat. 1990;28(12):1078–80.Google Scholar
  38. 38.
    Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49–57.Google Scholar
  39. 39.
    Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol. 2008;28(5):593–5.Google Scholar
  40. 40.
    Karp JF, Butters MA, Begley AE, Miller MD, Lenze EJ, Blumberger DM, Mulsant BH, Reynolds CF 3rd. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in mid-life and older adults. J Clin Psychiatry. 2014;75(8):e785–93.Google Scholar
  41. 41.
    Ehrich E, Turncliff R, Du Y, Leigh-Pemberton R, Fernandez E, Jones R, Fava M. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology. 2015;40:1448–55.Google Scholar
  42. 42.
    Yowell Y, Bar G, Mashiah M, Baruch Y, Briskman I, Asherov J, Lotan A, Rigbi A, Panksepp J. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173(5):491–8.Google Scholar
  43. 43.
    Guerdjikova A, Walsh B, Shan K, Halseth AE, Dunayevich E, McElroy SL. Concurrent improvement in both binge eating and depressive symptoms with naltrexone/bupropion therapy in overweight or obese subjects with major depressive disorder in an open-label, uncontrolled study. Adv Ther. 2017;34(10):2307–15.Google Scholar
  44. 44.
    Murphy B, Ravichandran C, Babb SM, Cohen BM. Naltrexone in bipolar disorder with depression: a double-blind, placebo-controlled study. Clin Psychopharmacol. 2014;34(6):749–51.Google Scholar
  45. 45.
    Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther. 1992;260(1):275–85.Google Scholar
  46. 46.
    Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, Hertrampf T, Kögel B, Schiene K, Straßburger W, Terlinden R, Tzschentke TM. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012;13(10):1437–49.Google Scholar
  47. 47.
    Shapira NA, Verduin ML, DeGraw JD. Treatment of refractory major depression with tramadol monotherapy. J Clin Psychiatry. 2001;62(3):205–6.Google Scholar
  48. 48.
    Spencer C. The efficacy of intramuscular tramadol as a rapid-onset antidepressant. Aust N Z J Psychiatry. 2000;34(6):1032–3.Google Scholar
  49. 49.
    Rougemont-Bücking A, Gamma F, Panksepp J. Use of tramadol in psychiatric care: a comprehensive review and report of two cases. Swiss Med Wkly. 2017;147:w14428.Google Scholar
  50. 50.
    Press release 14 January 2009. E-therapeutics. http://www.firstwordpharma.com/node/39762#axzz54JR5qryu.
  51. 51.
  52. 52.
    Stanley B, Siever L. The Interpersonal Dimension of borderline personality disorder: toward a neuropeptide model. Am J Psychiatry. 2010;167:24–39.Google Scholar
  53. 53.
    Stanley B, Sher L, Wilson S, Ekman R, Huang YY, Mann JJ. Non suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters. J Affect Disord. 2010;124(1–2):134–40.Google Scholar
  54. 54.
    Bresin K, Gordon KH. Endogenous opioids and nonsuicidal self-injury: a mechanism of affect regulation. Neurosci Biobehav Rev. 2013;37(3):374–83.Google Scholar
  55. 55.
    Resnick R, Falk F. Buprenorphine: pilot trials in borderline patients and opiate dependence—treatment of a common disorder? Monograph. In: Harris LS, editor. Problems of drug dependence. Washington, DC: National Institute on Drug Abuse Research; 1987. p. 155–68.Google Scholar
  56. 56.
    Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005;66(3):353–9.Google Scholar
  57. 57.
    Shapira NA, Keck PE Jr, Goldsmith TD, et al. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety. 1997;6:170–3.Google Scholar
  58. 58.
    Goldsmith TB, Shapira NA, Keck PE Jr. Rapid remission of OCD with tramadol hydrochloride. Am J Psychiatry. 1999;156:660–1.Google Scholar
  59. 59.
    Liddell Malcolm B, Aziz Victor, Briggs Patrick, Kanakkehewa Nimalee, Rawi Omar. Buprenorphine augmentation in the treatment of refractory obsessive–compulsive disorder. Ther Adv Psychopharmacol. 2013;3(1):15–9.Google Scholar
  60. 60.
    Ahmadpanah M, Reihani A, Ghaleiha A, Soltanian A, Haghighi M, Jahangard L, Sadeghi Bahmani D, Holsboer-Trachsler E, Brand S. Buprenorphine augmentation improved symptoms of OCD, compared to placebo—results from a randomized, double-blind and placebo-controlled clinical trial. J Psychiatr Res. 2017;94:23–8.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Brockton Neighborhood Health CenterBrocktonUSA
  2. 2.McLean HospitalBelmontUSA
  3. 3.Harvard Medical SchoolBostonUSA

Personalised recommendations